Page last updated: 2024-12-09

2-(2-fluorophenyl)-5-(4-methoxyanilino)-4-oxazolecarbonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(2-fluorophenyl)-5-(4-methoxyanilino)-4-oxazolecarbonitrile is a **small organic molecule**, often referred to by its abbreviated name **FPOCN**. It's important for research because of its potential as a **therapeutic agent** for various medical conditions.

**Here's a breakdown of its significance:**

* **Chemical Structure:**
* **Fluorophenyl** group: The fluorine atom on the phenyl ring can influence how the molecule interacts with biological targets.
* **Methoxyanilino** group: This group can impact the molecule's solubility and binding affinity.
* **Oxazole** ring: This ring system is often found in pharmaceuticals and plays a role in biological activity.
* **Carbonitrile** group: This group can contribute to the molecule's overall electronic properties.

* **Biological Activity:**
* FPOCN has been shown to exhibit **anti-inflammatory**, **anti-proliferative**, and **anti-angiogenic** properties.
* It has been investigated as a potential treatment for **cancer** and **inflammatory diseases** like rheumatoid arthritis.
* The molecule's ability to inhibit **kinase enzymes** may contribute to its therapeutic effects.

* **Research Focus:**
* Researchers are investigating the **mechanism of action** of FPOCN to understand how it interacts with biological targets.
* Studies are being conducted to determine its **pharmacokinetic properties** (how it's absorbed, distributed, metabolized, and excreted) and **safety profile**.
* Researchers are also exploring the potential of FPOCN as a **lead compound** for developing new drugs with improved efficacy and safety.

**In conclusion:**

FPOCN is a promising small organic molecule with potential therapeutic applications. Its unique chemical structure and demonstrated biological activity make it a valuable target for research in the field of drug discovery.

Cross-References

ID SourceID
PubMed CID949776
CHEMBL ID1507868
CHEBI ID120036

Synonyms (16)

Synonym
MLS000769529
smr000434244
2-(2-fluoro-phenyl)-5-(4-methoxy-phenylamino)-oxazole-4-carbonitrile
OPREA1_503154
CHEBI:120036
2-(2-fluorophenyl)-5-(4-methoxyanilino)-1,3-oxazole-4-carbonitrile
2-(2-fluorophenyl)-5-[(4-methoxyphenyl)amino]-1,3-oxazole-4-carbonitrile
STK896388
AKOS001655320
HMS2798J07
CHEMBL1507868
2-(2-fluorophenyl)-5-(4-methoxyanilino)-4-oxazolecarbonitrile
Q27207833
sr-01000104191
SR-01000104191-1
2-(2-fluorophenyl)-5-(4-methoxyanilino)-1,3-oxazol-4-yl cyanide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,3-oxazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency12.58930.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID485281
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
glp-1 receptor, partialHomo sapiens (human)Potency3.16230.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency31.62280.100020.879379.4328AID588456
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID504466
GLS proteinHomo sapiens (human)Potency19.95260.35487.935539.8107AID624170
Microtubule-associated protein tauHomo sapiens (human)Potency2.23870.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
alpha-galactosidaseHomo sapiens (human)Potency31.62284.466818.391635.4813AID1467
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency44.66840.036619.637650.1187AID1466; AID2242
ras-related protein Rab-9AHomo sapiens (human)Potency3.16230.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency44.66843.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency44.66843.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]